New trial combines HIV PrEP and STI prevention in one package for young men

NCT ID NCT07658976

Not yet recruiting Disease control Sponsor: HIV Prevention Trials Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to see if the tools improve PrEP use and reduce infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV PrEP (F/TDF, F/TAF, or CAB-LA) and STI PEP (doxycycline)
What this could lead to: If successful, this approach could make it easier for young men to stick with HIV prevention and reduce sexually transmitted infections.
What could go wrong: This is a Phase 3 trial, but results depend on real-world adherence and may not apply to all populations. The mHealth tools may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS hepatitis B virus infection HIV infectious disease prevention target sexually transmitted disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION SEXUALLY TRANSMITTED INFECTION

Contacts and locations

Locations

Bronx Prevention Research Center CRS

The Bronx, New York, 10451, United States
Fundacion Huesped CRS

Buenos Aires, C1427CEA, Argentina
Instituto de Pesquisa Clinicaq Evandro Chagas CRS

Manguinhos, Rio de Janeiro, 221045-900, Brazil
San Miguel CRS

Lima, 32-15088, Peru
UCLA Vine Street Clinic

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.